跳至主要内容
临床试验/CTRI/2011/11/002140
CTRI/2011/11/002140已完成2 期

â??A pilot study of efficacy of Lactobacillus CD2 lozenges in preventing high-dose chemotherapy induced oral mucositis in patients undergoing hematopoietic stem cell transplantationâ??

CD Pharma India pvt ltd0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age between 10 and 70 years.
  • 2.Karnofsky Performance Score >= 70%.
  • 3.Confirmed histological diagnosis of cancer/leukaemia for which haematopoietic stem cell transplantation is as approved modality of therapy.
  • 4.Patients eligible to receive high-dose chemotherapy as part of conditioning regime.
  • 5.Concomitant co morbid condition if present, controlled by medicines.
  • 6.Serum creatinine ï?¼ 1.8mg/dl.
  • 7.Total bilirubin ï?¼ 2mg/dl.
  • 8.Liver enzymes within three times of normal limit.
  • 9.Expected survival > 6 months.

排除标准

  • 1.Pregnant women and lactating mothers.
  • 2.Patients with history of AIDS
  • 3.Patients who have taken any other investigational product in last 4 weeks.
  • 4.Patients having untreated symptomatic dental infection.
  • 5.Patients with WHO Grade 3 or 4 oral Mucositis.
  • 6.Other serious concurrent illness.
  • 7.Inconclusive histological diagnosis.
  • 8.Patients on anticancer antibiotics.
  • 9.Patients with signs and symptoms of systemic infections.
  • 10.Patientâ??s/guardianâ??s refusal to sign informed consent.

研究者

相似试验